Regenerative Medicine Play Hits Snag
Shire's Dermagraft Fails in VLU Only Months After ABH Buyout
By Jennifer Boggs
Friday, August 26, 2011
Only two months after Shire plc shelled out $750 million in cash for Advanced BioHealing Inc. a move hailed as a rare win for investors in the regenerative medicine space the big pharma reported disappointing data from a pivotal trial aimed at expanding the use of ABH's lead product Dermagraft.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.